Letrozole-d<sub>4</sub>

Letrozole-d4

CAT N°: 26517
Price:

From 231.00 196.35

Letrozole-d4 is intended for use as an internal standard for the quantification of letrozole (Item No. 11568) by GC- or LC-MS. Letrozole is a potent, cell-permeable inhibitor of aromatase (IC50 = 2 nM).{23490} It inhibits proliferation of estrogen receptor-positive (ER+) MCF-7 cells when used alone at concentrations ranging from 0.1 to 100 nM and when used at a concentration of 10 nM in combination with testosterone or 4-androstene-3,17-dione.{46076} It also reduces matrix metalloproteinase-2 (MMP-2) and MMP-9 levels in MCF-7 cells when used at a concentration of 10 nM. Letrozole (10 µg per day) reduces tumor growth in an MCF-7Ca ovariectomized-mouse xenograft model.{46077} Formulations containing letrozole have been used in the treatment of postmenopausal breast cancer.{23489}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 4-[(4-cyanophenyl)-1H-1,2,4-triazol-1-ylmethyl]-benzonitrile-2,3,5,6-d4
  • Correlated keywords
    • CGS 20267 CGS20267 Femara deuterated deuterium LCMS GCMS MCF7 MMP2 MMP9 MCF7Ca
  • Product Overview:
    Letrozole-d4 is intended for use as an internal standard for the quantification of letrozole (Item No. 11568) by GC- or LC-MS. Letrozole is a potent, cell-permeable inhibitor of aromatase (IC50 = 2 nM).{23490} It inhibits proliferation of estrogen receptor-positive (ER+) MCF-7 cells when used alone at concentrations ranging from 0.1 to 100 nM and when used at a concentration of 10 nM in combination with testosterone or 4-androstene-3,17-dione.{46076} It also reduces matrix metalloproteinase-2 (MMP-2) and MMP-9 levels in MCF-7 cells when used at a concentration of 10 nM. Letrozole (10 µg per day) reduces tumor growth in an MCF-7Ca ovariectomized-mouse xenograft model.{46077} Formulations containing letrozole have been used in the treatment of postmenopausal breast cancer.{23489}

We also advise you